HDAC9 and ovarian cancer: The class I selective HDAC inhibitor romidepsin (FK228) is effective in reducing ovarian cancer cell proliferation at nanomolar concentrations [44], and multiple HDAC inhibitors are in ongoing cancer clinical trials [45],[46].